New blood filter could save lives in sudden liver failure

NCT ID NCT07178366

Not yet recruiting Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a blood purification device called DPMAS for people with acute-on-chronic liver failure (ACLF), a life-threatening condition. About 56 adults will be randomly assigned to standard medical care alone or standard care plus DPMAS. The goal is to see if DPMAS improves liver function and survival without needing a transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Double Plasma Molecular Adsorption System (DPMAS) - a blood purification device
What this could lead to: If it works, DPMAS could offer a way to stabilize liver function and improve survival without needing a transplant for people with acute-on-chronic liver failure.
What could go wrong: This is a small, early-stage trial with only 56 participants. The treatment is not a cure and may not work for everyone. There are also risks from the blood filtering procedure itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE-ON-CHRONIC LIVER FAILURE (ACLF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Acute-On-Chronic Liver Failure liver failure Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE-ON-CHRONIC LIVER FAILURE (ACLF)

More trials for these conditions

Other studies related to the condition(s) this trial covers.